Eric Venker Sells 100,000 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 100,000 shares of the stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $11.49, for a total transaction of $1,149,000.00. Following the sale, the chief operating officer now owns 595,580 shares of the company’s stock, valued at $6,843,214.20. This trade represents a 14.38 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Eric Venker also recently made the following trade(s):

• On Wednesday, November 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.32, for a total value of $1,132,000.00.
• On Monday, October 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.65, for a total value of $1,165,000.00.

Roivant Sciences Price Performance

NASDAQ:ROIV remained flat at $12.00 during trading hours on Thursday. The company’s stock had a trading volume of 3,300,963 shares, compared to its average volume of 5,778,284. Roivant Sciences Ltd. has a 1 year low of $9.69 and a 1 year high of $13.06. The company has a 50-day moving average price of $11.91 and a 200-day moving average price of $11.51. The firm has a market capitalization of $8.74 billion, a P/E ratio of 2.12 and a beta of 1.25.

Analysts Set New Price Targets

Several equities research analysts have recently commented on ROIV shares. Bank of America upped their price target on Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a research note on Wednesday, September 11th. Cantor Fitzgerald reissued an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, September 19th. Finally, HC Wainwright restated a “buy” rating and issued a $18.00 target price on shares of Roivant Sciences in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $17.93.

Hedge Funds Weigh In On Roivant Sciences

A number of large investors have recently made changes to their positions in ROIV. FMR LLC increased its holdings in Roivant Sciences by 5.6% in the third quarter. FMR LLC now owns 49,145,056 shares of the company’s stock valued at $567,134,000 after buying an additional 2,593,910 shares in the last quarter. Rubric Capital Management LP boosted its stake in shares of Roivant Sciences by 15.0% during the 2nd quarter. Rubric Capital Management LP now owns 23,000,000 shares of the company’s stock worth $243,110,000 after acquiring an additional 3,000,000 shares in the last quarter. State Street Corp grew its holdings in shares of Roivant Sciences by 6.1% in the 3rd quarter. State Street Corp now owns 19,561,249 shares of the company’s stock worth $225,737,000 after acquiring an additional 1,118,561 shares during the period. Geode Capital Management LLC grew its holdings in shares of Roivant Sciences by 23.2% in the 3rd quarter. Geode Capital Management LLC now owns 7,745,104 shares of the company’s stock worth $89,400,000 after acquiring an additional 1,460,205 shares during the period. Finally, DME Capital Management LP increased its stake in Roivant Sciences by 14.8% in the 2nd quarter. DME Capital Management LP now owns 4,810,960 shares of the company’s stock valued at $50,852,000 after purchasing an additional 620,470 shares in the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.